A simple and reliable protocol for mouse serum proteome profiling studies by use of two-dimensional electrophoresis and MALDI TOF/TOF mass spectrometry by Ritorto, Maria Stella & Borlak, Jürgen
BioMed  Central
Page 1 of 18
(page number not for citation purposes)
Proteome Science
Open Access Research
A simple and reliable protocol for mouse serum proteome profiling 
studies by use of two-dimensional electrophoresis and MALDI 
TOF/TOF mass spectrometry
Maria Stella Ritorto1 and Jürgen Borlak*1,2
Address: 1Department of Drug Research and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Nikolai-
Fuchs-Str 1, 30625, Hanover, Germany and 2Centre for Pharmacology and Toxicology, Hanover Medical School, Carl-Neuberg-Str 1, 30625, 
Hanover, Germany
Email: Maria Stella Ritorto - ritorto@item.fraunhofer.de; Jürgen Borlak* - borlak@item.fraunhofer.de
* Corresponding author    
Abstract
Background: Unravelling the serum proteome is the subject of intensified research. In this regard,
two-dimensional electrophoresis coupled with MALDI MS analysis is still one of the most
commonly used method. Despite some improvements, there is the need for better protocols to
enable comprehensive identification of serum proteins.
Here we report a combination of two proteomic strategies, zoom in acidic and neutral part of 2-
D gels and an application of two optimised matrix preparations for MALDI-MS analyses to simplify
serum proteome mapping.
Results: Mouse serum proteins were separated by 2-D electrophoresis at the pH ranges 3–10 and
4–7, respectively. Then in gel tryptic digests were analysed by MALDI-MS. Notably, sample-matrix
preparations consisted of either a thin-layer α-ciano-4-hydroxycinnamic acid (CHCA) matrix
deposition or a matrix-layer 2,5-dihydroxybenzoic acid (DHB). This enabled an identification of 90
proteins. The herein reported method enhanced identification of proteins by 32% when compared
with previously published studies of mouse serum proteins, using the same approaches.
Furthermore, experimental improvements of matrix preparations enabled automatic identification
of mouse proteins, even when one of the two matrices failed.
Conclusion: We report a simple and reliable protocol for serum proteome analysis that combines
an optimized resolution of 2-D gels spots and improved sample-matrix preparations for MALDI-
MS analysis. The protocol allowed automated data acquisition for both CHCA and DHB and
simplified the MS data acquisition therefore avoiding time-consuming procedures. The simplicity
and reliability of the developed protocol may be applied universally.
Background
From a disease diagnostic and drug monitoring point of
view there is great interest in serum proteome mapping of
humans and of laboratory animals. Indeed, various
mouse strains and genetically engineered animals are con-
sidered to be good models for human diseases as they
offer unprecedented opportunities for mechanistic studies
with new experimental medicines. There is hope that
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serum proteomics enables an identification of biomarkers
of disease and drug safety and serum proteins can be used
for therapeutic monitoring. In the past 2-D maps for
human serum have been reported [1-4]. And very recently
a map for the C57BL6 mouse serum proteome was pub-
lished [5].
In general, serum proteome profiling is challenging,
because of interference by high-abundance proteins such
as albumin, immunoglobulins, antitrypsin and transfer-
rin, which typically constitute greater than 90% of total
protein mass [1,2,6-9]. These abundant proteins may
hinder the detection of low-abundance proteins that can
be of specific interest in the search of biomarkers of dis-
ease. Additionally, protein biochips have been applied to
proteomic studies with antibody microarrays offering new
possibilities in the simultaneous identification of analytes
from complex samples [10].
So far, only a handful of plasma proteins are routinely
measured for diagnostic purposes, because an effective
technology that rapidly detects and quantifies specific
changes of proteins including low-abundance proteins of
serum is not available. As summarized elsewhere [11], the
most common methods for serum proteome studies
include separation of proteins by gel electrophoresis, exci-
sion of spots from the gel, enzymatic digestion and anal-
ysis by mass spectrometry. In particular, pre-fractionation
techniques such as serum albumin depletion are useful
procedures in proteome profiling studies, but they may
introduce bias as well. There is substantial run-to-run var-
iation after albumin depletion with IgY immunoaffinity
spin columns. Likewise, pre-fractionation increases the
risk of depletion of low-abundance proteins as has been
shown for paraneoplastic antigen MA I, coagulation factor
VII precursor, prostate-specific antigen, as a result of mul-
tiple protein-protein interactions with IgG, transferrins,
and/or gelsolin [11,12].
In this regard, MALDI-MS is considered to be one of the
most powerful techniques for the analysis of proteins and
peptides [13-15], but the sample matrix preparation
greatly influences the quality of MALDI-MS spectra of
peptides and therefore protein identification. Despite
considerable knowledge in the use of MALDI-MS [15-18],
sample-matrix preparations are basically empirical.
Here we report a protocol for serum proteome profiling
based on zoom in gels in the acidic and neutral pH that
enabled detection of many serum proteins. Moreover, the
developed protocol allowed for an automated data acqui-
sition, and the sample protocol was optimised by the use
of two different matrix-sample preparations in sequence
[19]. We thus applied tryptic in-gel digest matrix prepara-
tion to either α-ciano-4-hydroxycinnamic acid (CHCA) or
2, 5-dihydroxybenzoic acid (DHB) as recently reported by
us [19].
Materials and methods
Serum sample preparation
C57/BL6 mice (healthy mice) were obtained from Harlan
Winkelman (Borchen, Germany) and kept in an animal
house with 12 hour of light and dark cycled. Food and
water was given ad libitum. Blood serum was collected
from vena cava and allowed to clot for 2 hours at room
temperature. The clotted material was removed by centrif-
ugation at 3000 rpm for 15 min. Hemolytic material was
not observed. The sera obtained from the blood samples
were frozen immediately without any further treatment in
liquid nitrogen and stored at -80°C until further analysis.
The protein concentration of serum was determined with
the Bradford protein assay (Bio-Rad Protein Assay Dye
Reagent Concentrate, Bio-Rad), using bovine gamma
globulin as the standard. The protein concentration
ranged from 80 to 90 μg/μl for wild type mouse serum
samples.
Materials
IPG strips of pH 3 to 10 and 4 to 7 (ReadyStrip, 0.5 × 3 ×
170 mm; BioRad, Germany), Bio-Lyte (pH 3 to 10), SDS,
acrylamide, methylenebisacrylamide, TEMED, ammo-
nium persulfate, DTT, urea, Tris, glycine, glycerol, and
CHAPS were purchased from Bio-Rad. Alpha-cyano-4-
hydroxycinnamic acid (CHCA) and 2,5 dihydroxybenzoic acid
(DHB) from Bruker Daltonics. Methanol, ethanol, phos-
phoric acid, acetic acid, and formaldehyde were pur-
chased from Merck (Darmstadt, Germany). Sequencing
grade modified trypsin was obtained from Promega
(Madison, WI, USA).
Coomassie Brilliant Blue G-250, TCA, iodoacetamide and
other reagents were obtained from Sigma (St. Louis, MO,
USA).
Two-dimensional electrophoresis
IEF was carried out using commercially available, dedi-
cated apparatuses: IPGphor Protean IEF Cell (Bio-Rad).
IPG strips were used according to manufacturer instruc-
tions [see also [20]]. About 500 μg of serum for gel were
diluted to 350 μL with re-hydration solution (5 M urea, 2
M Thiourea, 2% CHAPS, 100 mM DTT, 0.5% v/v pH 3 to
10 IPG buffer, 40 mM Tris Base, 2% SB 3–10 and trace
bromophenol blue), and applied to immobilized pH 3 to
10 nonlinear and pH 4 to 7 linear gradient strips by over-
night re-hydration at 50 V. With Protean IEF Cell, focusing
was done initially at 250 V for 15 min, then the voltage
was increased to 10 000 V within 3 h, and maintained at
10 000 V for 7 h for a total of 70 kVh. All IEF steps were
carried out at 20°C. After the first-dimensional IEF, IPG
gel strips were placed in an equilibration solution (6 MProteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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urea, 2% SDS, 30% glycerol, 50 mM Tris-HCl, pH 8.8)
containing 1% DTT for 10 min with shaking at 50 rpm on
an orbital shaker. The gels were then transferred to the
equilibration solution containing 2.5% iodoacetamide
and shaken for a further 10 min before placing them on
12% polyacrylamide gel slab (185 × 200 × 1.0 mm).
Separation in the second dimension was carried out using
Protean II electrophoresis equipment and Tris-glycine
buffer (25 mM Tris, 192 mM glycine) containing 0.1%
SDS, at a current setting of 5 mA/gel for the initial 1 h and
10 mA/gel thereafter. The second-dimensional SDS-PAGE
was developed until the bromophenol blue dye marker
had reached the bottom of the gel.
Protein visualization and image analysis
Following second-dimensional SDS-PAGE, analytical gels
were fixed three times in 30% ethanol containing 2%
phosphoric acid for 20 min and rinsed three times in 2%
phosphoric acid. Gels were then equilibrated in a solution
containing 18% ethanol, 2% phosphoric acid, and 15%
ammonium sulfate for 30 min and Coomassie Brilliant
Blue G-250 was added to a final concentration of 1%.
Staining was carried out overnight. Protein patterns in the
gels were recorded as digitalized images using a high-res-
olution scanner (Pharox FX, Bio-Rad). Gel image match-
ing was done with PDQuest software (Version 8.01.40;
Bio-Rad). Scanned gel images were processed to remove
backgrounds, staining on the gel borders and to automat-
ically detect spots. For all spot intensity calculations, nor-
malized values were used. Normalization of spot intensity
was done with Loess Regression Method and normalized
spot intensities were expressed in ppm.
In-gel digestion
In-gel digestion of protein spots on Coomassie gels was
carried out with 160 ng of Porcine Modified Trypsin
(Sigma) in 10% ACN and 25 mM NH4HCO3 and per-
formed essentially as described below.
Briefly, after the completion of staining, the gel were
washed twice with water for 15 min, and then twice with
water/ACN (1:1 v/v) for 15 min. The solvent volumes
were about twice the gel volume. Liquid was removed,
ACN was added to the gel pieces and the mixture was left
for 5 min. Liquid was removed and the gel pieces were re-
hydrated in 0.1 M NH4HCO3 for 5 min. ACN was added
to give a 1:1 v/v mixture of 0.1 M NH4HCO3/ACN and the
mixture was incubated for 15 min. All liquid was removed
the digestion buffer containing 25 mM NH4HCO3 and 10
ng/μL of trypsin was added and all was incubated for 4
hours at 37°C. The supernatant was recovered and the
extraction was carried out with 1% TFA/ACN (1:1 v/v).
MALDI-TOF-MS, MS/MS and database search
Tryptic peptides were spotted directly onto a 600 μm/384
well AnchorChip™ sample target (Bruker Daltonics). The
matrix CHCA was saturated in 97% Acetone/0.1% TFA
solution; DHB matrix was solved in 30% ACN/0.1% TFA
solution (5 mg/ml). The matrix-analyte preparations were
loaded onto the MALDI plate (AnchorChip™ 600 mm 384
well, Bruker Diagnostic) by the thin layer and the matrix
layer (ML) method for CHCA and DHB respectively. A fur-
ther re-crystallization approach was tested on peptide cal-
ibration standard preparation (Bruker Daltonics) and
applied for the samples on the AnchorChip™ [19]. An
external peptide calibration standard containing the fol-
lowing fragments was used to calibrate the instrument:
angiotensin II ([M+H]+ 1046.54); angiotensin I ([M+H]+
1296.680); substance P ([M+H]+ 1347.740); bombesin
([M+H]+ 1619.820); ACTH clip 1–17 ([M+H]+
2093.090); ACTH clip 18–39 ([M+H]+ 2465.200); soma-
tostatin 28 ([M+H]+ 1347.470) (Bruker Daltonics). Fur-
thermore, the spectra were calibrated using trypsin
autolysis products (m/zs  1045.564, 2211.108 and
2225.119) for three points internal calibration resulting
in a mass accuracy of <50 ppm.
The MALDI mass spectra were obtained using an Ultraflex
II TOF/TOF mass spectrometer equipped with a 384-sam-
ple scout source (Bruker Daltonics) and AutoXecute® soft-
ware for automatic spectra acquisition (Bruker Daltonics)
was used. Peptide masses were searched against SwissProt
database employing Mascot (in-house MASCOT-server)
for protein identification. Database searches were per-
formed taking into account carbamidomethyl modifica-
tion of cysteines and possible oxidation of methionine
and allowing one missed cleavage. The mass accuracy
required for PMF and MS/MS was basically chosen accord-
ing to peptide mass-tolerance defined by Root Mean
Square (RMS) error, since it defines the limit of peptide
mass tolerance (Peptide tol +-) for respectively Mascot Pep-
tide Mass Fingerprint and Mascot MS/MS Ion Search to
obtain a significant score (p < 0.05) of matched peptides
to select protein entry [21].
Peptides were identified using ProteinScape™ database
(Protagen, Bruker, Germany) and Mascot search engine to
cross-validate or consolidate the identification results
through the complementary use of several software pack-
ages. We use ProteinScape™ ScoreBooster feature to
improve database search results by automatic iterative rec-
alibrations and background eliminations. Identified pro-
teins were checked individually for further considerations.
The criteria used to accept identifications included the
extent of sequence coverage, the number of matched pep-
tides, the Mascot score, i.e. the Top Score obtained after
Mascot has incorporated the Mowse score into a probabi-Proteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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listic framework. It is defined as -10*LOG10(P), where P is
the absolute probability that the observed match is a ran-
dom event [21]. In case of SwissProt as selected protein
sequence database, protein scores greater than 53 were
significant (p < 0.05). In addition we requested mouse
protein as the top candidates in the first pass search when
no restriction was applied to the species of origin. Moreo-
ver, when the identification was not possible to reach
from PMF, MS/MS data were collected and used as result,
if  Significant hits were obtained by Probability Based
Mowse Score (individual ion scores >25 that indicate
identity or extensive homology-p < 0.05-) [21]. In general,
false positive evaluation was done by software with rand-
omized searches to remove redundant peptide and pro-
tein identification.
The new identifications were furthermore searched in
PeptideMap free software (ProWL free software programs,
National Resource for the Mass Spectrometric Analysis of
Biological Macromolecules, the Rockefeller University)
[22] and compared with Mascot results (for details, please
refer to Additional files 1, 2).
Results and discussion
Two-dimensional electrophoresis of serum proteins
We found narrow 2-D gels to improve detection of low
abundant proteins in sera, thereby avoiding any pre-frac-
tionation. The 2-DE proteomics carries the advantage of
visualizing changes in Mw and pI of a protein, which we
find helpful in highlighting biologically significant proc-
esses. This electrophoresis technique has been applied
successfully to identify oncoproteins in human serum and
tissues [11,13,20,23]. Notably, mouse serum proteins
were separated by 2-D electrophoresis (2-DE) and
resolved in the first dimension in a broad pH range with
IPGphor strips (pH 3 to 10 NL), and subsequently in a
12% gradient polyacrylamide SDS gel in the second
dimension. On average, 350 spots could be detected and
77 unique mouse proteins were identified, of which more
than 30% were in the basic region of the gel (Figure 1).
Among them, we identified some proteins already known
or evaluated as potential biomarkers for human malig-
nancies. For instance, previous studies have shown the
benefit of studying complement factors in human cancer,
i.e. elevated CO3 levels identified in pancreatic cancer
patients. Consequently, monitoring activity of CO3/CO4
is clinically relevant [24-26]. Moreover, heme in tissues
and circulation may be come toxic due to oxygen radical
formation. Hemopexin, a plasma protein binds heme
with high affinity, and therefore limits its reactivity
thereby facilitating its catabolism via receptor-mediated
endocytosis. Furthermore, the heme-hemopexin complex
is glycosilated at specific Hys residues. Obviously, moni-
toring the precursor at basic pH and its glycosilated form
at acidic pH can be informative as biomarker of disease
[27,28]. Likewise, we identified tryptophan 5-hydroxylase
1 (TPH1_MOUSE) in the serum proteome. This protein
promotes the synthesis of 5-HT (serotonin). Intriguingly,
a recent investigation has found its involvement in the
regulation of the immunosystem and aberrant activity in
cancers [29,30].
As shown in Figure 2 the sample complexity was further
reduced by the use of IPG strips in the pH range of 4 to 7.
The number of spots was increased by 2-fold. Approxi-
mately 660 spots were detected and 59 proteins were
identified in this pH range. When compared with gels of
the 3 to 10 pH-range, multiple isoforms of proteins can
now be visualised and may have arisen from a combina-
tion of post-translational modifications as well as chemi-
cal modifications that occur during sample preparation
(Figure 2) [20,31]. Apart from high abundant proteins, on
average three spots for each protein at pH of 4 to 7 could
be detected, when compared to one spot for each entry or
smears observed with gels at pH of 3 to 10 (Figure 2).
Altogether, the spot detection was improved and a total of
16 of these proteins were novel gene products resolved at
pH 4 to 7 (Table 1, italic font). Notably, 4 of them had not
been reported so far in mouse serum [5-9,32,33].
Improved MALDI TOF-MS analysis of serum proteins
To increase the number of ionized tryptic-digested pep-
tides, we took advantage of the properties of two com-
monly used matrices, CHCA and DHB [15,19]. To the best
of our knowledge sample-matrix preparations with both
matrices in sequence for serum proteome profiling has
not been reported so far. These matrices differ considera-
bly upon MALDI ionization. We combined a thin layer
and the ML deposition on the AnchorChip™ to identify 2-
D spots from mouse serum samples using a protocol
recently described by us [19]. Briefly, we used a Bruker
MALDI target plate, equipped with hydrophilic patches
("anchors") in hydrophobic surroundings (AnchorChip™,
Bruker Daltonics), and achieved signal uniformity, high
sensitivity and an improved signal-to-noise ratio which
gave rise to less complex MS spectra of which an example
is given in Figure 2. Moreover, the re-crystallization of the
sample-matrix mixtures loaded on the target increased
considerably the number of identifiable peptide ions in
an automated MS and MS/MS spectra acquisition mode
(see also Table 1). Striking differences in the MALDI MS
spectra of peptides were observed when the two matrices
were compared (Figure 3). We observed better ionization
of peptides from the tryptic-digested proteins with DHB
as compared with CHCA. Indeed with CHCA, we fre-
quently observed peaks at m/z 1044, 1060, 1066, 1082,
1249 and 1271 (Figure 3, azure cycles). We used matrix
ion suppression in deflection mode of m/z 800. These
abundant matrix clusters display high s/n ratio and
resulted in poor acquired PMF spectra [11,34]. PreviousProteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
Page 5 of 18
(page number not for citation purposes)
reports had already highlighted differences in PMF
because of different behaviour of the two matrices
[15,16,18]. In particular, Zhu and Papayannopoulos
tested several matrices and reported that DHB gave the
best results without interferences from matrix ion peaks.
Furthermore, common interferences from matrix-adducts
of CHCA were observed, in particular in the range of m/z
800–1100 of the MALDI spectra [35].
Nonetheless, there are obvious benefits in the use of the
CHCA matrix in the MALDI MS analysis. This included a
high uniform layer, which it forms, especially on the
AnchorChip™ (data not shown). Its ability to induce des-
orption of ions at lower laser energies demonstrates trans-
fer of sufficient energy for the pre-formation of ions. In
some cases, metastable ions of matrix ion fragments were
less formed when compared with DHB [36]. This enabled
acquisition of less ambiguous spectra for the identifica-
tion of proteins. The different behaviours of both matrices
are the subject of several published studies. In particular,
Luo et al. [37] reported loss of internal energy of ions gen-
erated by MALDI and the role of the two matrices in des-
orption and ionisation processes.
Indeed, in a complex mixture such as serum, it is not really
clear why in some cases diagnostic PMFs are obtained
with DHB rather than CHCA and vice versa. Some exam-
ples, depicted in Figure 3, clearly demonstrate that it is dif-
ficult to predict which matrix would deliver best PMFs.
For that reason, we exploited both matrices in order to
redress any drawbacks of one matrix by the use of the
other one especially in automatic data acquisition proce-
dures.
Protein entries at basic region of 3–10 pH range Figure 1
Protein entries at basic region of 3–10 pH range. An amount of 23 proteins were identified at basic region of gels at pH 
range 3–10. As discussed in the text, most of those proteins could be relevant in biomarker discovery research because of 
their involvement in inflammation or in mechanisms that could bring toward the development of cancer.P
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Table 1: Mouse serum protein map
No. SwissProt 
entry
SwissProt 
accession
Mw 
(KDa)
pI Mascot 
score
sequence 
coverage 
(%)
msms (m/z) matrix Our Map 1 
(matched 
peptides)
Ref Map 2 
(matched 
peptides)
Ref Map 3 
(matched 
peptides)
Ref Map 4 
(matched 
peptides)
Ref Map 5 
(matched 
peptides)
Ref Map 6 
(matched 
peptides)
1 A1AG1 
MOUSE
Q60590 24 5.6 124 32 1703.91 CHCA 
DHB
10 not present 41 2 5  ( u p  
regulated)
present
2A M B P  
MOUSE
Q07456 40 6 38 4 1669.85 CHCA  1 3* not present not present not present not present
3 APOM 
MOUSE
Q9Z1R3 21.6 6 105 36 938.42 CHCA 
DHB
9 not present not present not present not present present
4 MUP1 
MOUSE
P11588 20.9 5 115 55 DHB 12 0 10 not present not present not present
MUP2 
MOUSE
P11589 20.9 5 146 68 DHB 14 0 11 19 not present not present
MUP6 
MOUSE
P02762 20.9 5 136 62 DHB 12 0 10 not present not present not present
MUP8 
MOUSE
P04938 17.7 5 141 74 DHB 12 0 10 not present not present not present
5 A1AT1 
MOUSE
P07758 46.1 5.4 145 41 981.56
1137.66
1232.70
2003.04
2327.09
2405.17
3498.80
CHCA 
DHB
15 10*
2'
13 12 20 (up 
regulated)
not present
A1AT2 
MOUSE
P22599 46.1 5.3 104 36 2405.17
2003.04
2327.09
3498.80
CHCA 
DHB
12 9' not present 73  ( u p  
regulated)
present
A1AT3 
MOUSE
Q00896 46 5.3 146 44 981.56
1137.66
2003.04
2327.09
2405.17
3498.80
CHCA 
DHB
15 not present 16 15 not present not present
A1AT4 
MOUSE
Q00897 46.1 5.2 162 51 1232.74
2003.04
2327.09
3498.80
CHCA 
DHB
17 not present not present not present not present present
A1AT5 
MOUSE
Q00898 46 5.4 105 35 1232.71
2327.09
2405.17
CHCA 
DHB
12 not present not present not present not present present
A1AT6 
MOUSE
P81105 46 5.2 161 47 981.56
1137.66
1232.70
2003.04
2327.09
2405.17
3498.80
CHCA 
DHB
16 2 not present 8 not present present
6 ANT3 
MOUSE
P32261 52.5 6.1 298 56 1198.70
1340.69
1359.67
1700.89
CHCA 
DHB
29 6 not present not present not present presentP
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7 A2AP 
MOUSE
Q61247 55.1 5.8 169 36 1591.80
1680.81
CHCA 
DHB
15 3 not present not present not present present
8 CBG 
MOUSE
Q06770 44.9 5 148 32 CHCA 
DHB
10 3 not present not present not present present
9 SPA3K 
MOUSE
P07759 47 5 113 29 CHCA 
DHB
12 12 not present 21 7 (up 
regulated)
present
10 A2MG 
MOUSE
Q61838 167 6.3 153 19 2068.21 CHCA 
DHB
18 25 16 (immuno 
depletion)
not present not present present
10a A2MG 
MOUSE C-
term
Q61839 28 7 62 6 1031.50
1111.58
1216.61
1787.96
CHCA 
DHB
9? not present 13 16 (up 
regulated)
present
11 ADIPO 
MOUSE
Q60994 26.9 5.3 63 19 1504.72 DHB 5 not present not present not present not present present
12 AFAM 
MOUSE
O89020 71.5 5.5 155 31 CHCA 
DHB
15 1 9 not present not present present
13 ALBU 
MOUSE
P07724 70.7 5.7 426 68 1455.83
1479.70
1609.90
1882.96
1960.15
1981.98
CHCA 
DHB
40 26*
46'
17 48 12 (up 
regulated)
present
14 ALS MOUSE P70389 67.7 6.1 97 28 DHB 13 not present not present not present not present present
15 CPN2 
MOUSE
Q9DBB9 61.3 5.5 131 25 CHCA 10 not present not present not present not present present
16 ANGL6 
MOUSE
Q8R0Z6 51.4 9.2 56 16 DHB 4 not present not present not present not present not present
17 ANXA2 
MOUSE
P07356 38.8 7.5 82 18 CHCA 5 not present not present not present not present not present
18 APOA1 
MOUSE
Q00623 30.5 5.6 207 49 1237.67
1318.61
1331.53
1340.77
CHCA 
DHB
17 5*
18'
13 18 22 present
19 APOA2 
MOUSE
P09813 11.3 6.6 85 14 1193.62
1831.98
CHCA 
DHB
24 '73 3  ( u p  
regulated)
present
20 APOA4 
MOUSE
P06728 45 5.4 223 60 1131.66
1231.61
1461.75
2023.05
CHCA 
DHB
21 2*
5'
15 29 6 (up 
regulated)
present
21 APOE 
MOUSE
P08226 35.9 5.6 166 51 968.52
1075.60
1599.82
CHCA 
DHB
21 5' 7 17 16 (up 
regulated)
present
22 APOC3 
MOUSE
P33622 10.9 4.6 140 19 1062.46
1078.45
1987.94
CHCA 3 not present 33 not present present
23 APOH 
MOUSE
Q01339 39.9 8.6 276 62 1325.68
1544.85
2719.48
CHCA 
DHB
22 7 not present 17 22 (up 
regulated)
present
24 CLUS 
MOUSE
Q06890 55.2 5.5 103 19 CHCA 
DHB
11 2* 9 12 not present present
25 C1R MOUSE Q8CG16 81.5 5.4 78 17 CHCA 8 not present not present not present not present not present
26 CFAB 
MOUSE
P04186 86.3 7.2 269 37 CHCA 
DHB
23 3 not present not present not present present
27 CFAI MOUSE Q61129 69.5 7.4 103 21 1726.85 DHB 11 3 not present not present not present not present
Table 1: Mouse serum protein map (Continued)P
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28 HGFA 
MOUSE
Q9R098 72.9 6.6 58 13 DHB 6 not present not present not present not present present
29 HPT MOUSE Q61646 39.2 5.9 146 49 980.49
1320.74
1373.61
DHB 21 not present 11 5 14-3 (up and 
down 
regulated)
present
29a HPT MOUSE Q61646 81 11 1679.78 DHB 6 ? ? 14 ? not present
30 PLMN 
MOUSE
P20918 93.4 6.2 387 53 1138.46 CHCA 
DHB
35 8 not present 32 6 present
31 CFAH 
MOUSE
P06909 144 6.6 269 31 CHCA 
DHB
29 6 not present 18 not present present
32 CS1A MOUSE Q8CG14 78.3 5 66 15 DHB 6 not present not present not present not present not present
33 F13B 
MOUSE
Q07968 78.3 5.6 148 26 CHCA 15 not present not present not present not present present
34 CO3 
MOUSE
P01027 188 6.4 312 29 1886.93 CHCA 
DHB
40 23*
1'
not present not present 17 (up 
regulated)
present
35 CO4 
MOUSE
P01029 194 7.5 123 9 CHCA 14 3 not present not present not present present
36 CO9 
MOUSE
P06683 63.2 5.6 80 29 DHB 14 1 not present not present not present not present
37 C1QB 
MOUSE
P14106 27 8.6 69 20 CHCA 51 * not present not present not present present
38 EGFR 
MOUSE
Q01279 138 6.5 171 16 CHCA 
DHB
15 not present not present 18 not present present
39 FIBB MOUSE Q8K0E8 55.4 6.7 112 39 CHCA 
DHB
20 not present not present not present not present present
40 FINC 
MOUSE
P11276 276 5.4 90 8 CHCA 16 9* not present not present not present present
41 FCN1 
MOUSE
O70165 36.8 6 65 12 DHB 5 not present not present 8 not present not present
42 FETUA 
MOUSE
P29699 38.1 6 135 47 1653.75 
2138
CHCA 
DHB
11 3 6 8 not present present
43 FETUB 
MOUSE
Q9QXC1 43.5 6.2 113 30 1382.89
1159.7
CHCA 
DHB
14 1 5 13 not present present
44 GPX3 
MOUSE
P46412 25.6 8.3 98 45 1955 CHCA 
DHB
12 not present not present not present not present present
45 HA10 
MOUSE
P01898 37.2 5.2 173 46 1671.86 CHCA 
DHB
16 3 not present not present not present not present
46 HBA 
MOUSE
P01942 15 8 79 31 1589.82
1819.93
CHCA 5 2*
6'
not present not present 8p r e s e n t
47 HBB1 
MOUSE
P02088 16 7.3 68 73 1274.72 CHCA 
DHB
9 not present not present not present 7 (up 
regulated)
present
48 HEMO 
MOUSE
Q91X72 52 7.9 188 43 1100.47
1212.63
1504.76
1516.71
1727.77
2472.12
CHCA 
DHB
21 14 8 25 3 (up 
regulated)
present
49 IGHG1 
MOUSE
P01868 36.2 7.2 94 45 DHB 9 3 not present not present not present not present
50 KNG1 
MOUSE
O08677 74.1 6 164 29 1010.56
1060.56
1515.68
CHCA 
DHB
18 9 12 24 5 (up 
regulated)
not present
51 KLKB1 
MOUSE
P26262 73.4 8.4 105 22 CHCA 14 1* 2 not present not present present
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52 KV3A1/2/4 
MOUSE
P01654 12 5 116 16 1616.89
1855.04
CHCA 
DHB
2 not present not present not present not present present
KV3AD 
MOUSE
P01665 12 4.9 54 44 1155.46
1616.89
1855.04
CHCA 
DHB
4 not present not present not present not present present
53 KV5AB 
MOUSE
P01644 12 7.9 88 17 1028.56
1926.92
2455.35
CHCA 
DHB
3 not present not present not present not present not present
KV5J 
MOUSE
P01645 11.9 9.2 93 16 1926.81 CHCA 
DHB
1 not present not present not present not present present
54 KV3N 
MOUSE
P01666 12 4.5 58 53 DHB 3 not present not present not present not present present
55 MUC 
MOUSE
P01872 50 6.6 184 30 1330.78
1603.91
CHCA 
DHB
14 4 not present not present not present not present
56 MUG1 
MOUSE
P28665 
(Q80XE6)
166.4 6 168 20 CHCA 
DHB
24 12 not present not present not present present
57 PHLD 
MOUSE
O70362 93.8 6.6 151 23 CHCA 
DHB
20 1 not present not present not present present
58 PON1 
MOUSE
P52430 34.6 5 117 32 1853.9 CHCA 
DHB
82 not present not present not present present
59 PROP 
MOUSE
P11680 50 8.4 87 21 CHCA 8 not present not present not present not present present
60 RETBP 
MOUSE
Q00724 23.5 5.7 138 59 1226.63
1360.58
1789.84
2079.88
CHCA 
DHB
15 1 not present not present not present present
61 SAMP 
MOUSE
P12246 26.4 6 88 38 2133.03 CHCA 
DHB
8188 not present present
62 THRB 
MOUSE
P19221 71.6 6 156 28 1189.56 CHCA 
DHB
19 4 not present 26 9 (up 
regulated)
present
63 TRFE 
MOUSE
Q921I1 78.8 7 308 51 1171.61
1419.86
1656.81
1990.82
2007.94
CHCA 
DHB
38 39*
1'
?2 6 not present present
64 KAC 
MOUSE
P01837 11.9 5 91 87 990.51 CHCA 
DHB
81 not present not present not present not present
65 ZA2G 
MOUSE
Q64726 35.4 5.8 173 55 1274.60
1318.81
1409.72
1610.74
CHCA 
DHB
15 1 not present 19 not present present
66 VTDB 
MOUSE
P21614 55.1 5.4 266 44 1051.6
1303.77
2441.13
CHCA 
DHB
24 3 12 31 not present present
67 TTHY 
MOUSE
P07309 15.9 5.8 122 67 1382.62
1554.89
2438.17
2517.22
CHCA 
DHB
84 *
1'
10 9 not present present
68 GELS 
MOUSE
P13020 86.3 5.8 233 39 1254.75
1275.73
CHCA 
DHB
22 6 not present 19 not present present
69 VTNC 
MOUSE
P29788 55.6 5.7 82 23 CHCA 
DHB
10 2 not present not present not present present
70 GCAB 
MOUSE
P01864 37 8.5 31.5 5 1913.84 DHB 1 2 
(membrane 
form)
not present not present not present not present
Table 1: Mouse serum protein map (Continued)P
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71 GCB 
MOUSE
P01866 37.3 7.2 79 30 1778.87 CHCA 
DHB
8 3 
(membran
e form)
not present not present not present not present
72 LAC1 
MOUSE
P01843 11.7 5.9 70 61 DHB 4 not present not present not present not present not present
73 LAC2 
MOUSE
P01844 11.4 5.9 70 89 DHB 5 not present not present not present not present present
74 ACTG 
MOUSE
P63260 42.1 5.3 188 53 1198.75
1790.93
1954.14
CHCA 
DHB
16 not present not present not present not present not present
ACTB 
MOUSE
P60710 42 5.3 171 49 1198.75
1790.93
1954.14
CHCA 
DHB
15 not present not present not present not present present
75 APC MOUSE Q61315 313 7.4 53 6 CHCA 15 not present not present not present not present present
76 CT160 
MOUSE
Q8VCC6 22 9.5 56 20 CHCA 5 not present not present not present not present not present
77 CUL1 MOUSE Q9WTX6 90.3 8.2 62 15 CHCA 7 not present not present not present not present not present
78 ESTN 
MOUSE
P23953 61.4 5.1 168 37 911.45 CHCA 
DHB
21 12 7 not present not present present
79 ITIH2 
MOUSE
Q61703 106 6.8 150 24 1337.73 CHCA 
DHB
14 2 not present not present not present present
80 ITIH4 
MOUSE
9055252 104.8 6 133 20 CHCA 17 not present not present 18 not present not present
81 K2C5 
MOUSE
Q922U2 62 7.6 60 16 DHB 11 not present not present not present not present not present
82 LIFR MOUSE P42703 123.8 5.7 151 19 DHB 15 not present not present 22 not present present
83 MBL1 
MOUSE
P39039 25.8 7.5 100 27 1544.89 CHCA 9 not present not present not present 8 (up 
regulated)
present
84 MBL2 
MOUSE
P41317 26.3 5 70 29 1323.60
1522.72
1766.83
CHCA 
DHB
62 not present 8 not present not present
85 OST5 
MOUSE
Q8BSL4 40.7 9.7 70 23 CHCA 6 not present not present not present not present not present
86 SYT2 
MOUSE
P46097 47.7 8.2 61 19 CHCA 6 not present not present not present not present present
87 TPH1 
MOUSE
P17532 51.9 6 59 17 CHCA 7 not present not present not present not present not present
88 KPYM 
MOUSE
P52480 58 7 53 30 DHB 12 not present not present not present not present not present
89 DYN2 
MOUSE
P39054 98 7 68 12 CHCA 
DHB
9 not present not present not present not present not present
90 GAB2 
MOUSE 
Q9Z1S8 73.6 8.5 33 2 1794.8 DHB 1 not present not present not present not present present
Mouse serum proteins identified by us in serum from C57BL6 mice (Our Mapping 1), in comparison with previous mouse serum maps (Ref Map 2: [9], Ref Map 3: [8], Ref Map 4: [7,32], Ref Map 5: ref 
[33] and Ref Map 6: [6]). Exactly, 16 of them (italic font) were identified only by narrow IPGs of pH 4–7. In bold, we highlighted the proteins identified only with LIFT-MS/MS measurements. In case of 
TCA/methanol precipitation method (Ref Map 2: [9]) we specified where the proteins were identified. (n*: precipitated fraction; n': supernatant fraction-). In the case of MUPs, we marked with 0 the 
entries, because there are evidences that those proteins are present just in C57BL6 mice and not in BALA/cj inbred strain [32].
Table 1: Mouse serum protein map (Continued)Proteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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Improved resolution with zoom-in 2-D gels Figure 2
Improved resolution with zoom-in 2-D gels. Details of the 2-D gel zoomed areas. We showed the improved separation 
and visualization of the mouse serum proteome. In fact, multiple isoforms for most identified proteins were found and other 
identified spots were detected only in 4–7 pH-range and not in 3–10 pH-range. Panel 1: 3–10 pH range (1 spot 1 id: mouse cer-
uloplasmin; 4 spots 1 id: mouse gelsolin) 4–7 pH range (14 spots 3 ids: mouse ceruloplasmin, mouse alpha-macroglobulin, mouse albu-
min; 6 spots 1 id: mouse gelsolin; 3 spots 1 id: mouse hemopexin).Panel 2: 3–10 pH range (1 smear 2 ids: mouse afamin and mouse 
hemopexin; 1 smear 1 id: mouse kininogen; 1 smear 2 ids: mouse antithrombin-III, mouse Alpha-2-HS-glycoprotein) 4–7 pH range (3 
spots 1 id: mouse prothrombin; 3 spots 1 Id: mouse hemopexin; 3 spots 1 id: mouse kininogen; 6 spots 4 ids: mouse antithrombin-III, 
mouse Alpha-2-HS-glycoprotein, mouse vitamin D-binding protein and mouse fetuin-b).Panel 3: 3–10 pH range (3 spots 2 ids: mouse 
apolipoprotein A4 and mouse zinc-alpha-2-glycoprotein; 1 spot 1 id: mouse albumin) 4–7 pH range (1 spot 1 id: mouse serum paraox-
onase/arylesterase 1; 1 spot 1 id: mouse H-2 class I histocompatibility antigen; 3 spots 1 id: mouse alpha-2-macroglobulin). Panel 4: 3–
10 pH range (3 spots 1 id: mouse apolipoprotein A1) 4–7 pH range (1 spot 1 id: mouse mannose-binding protein2; 4 spots 1 id: 
mouse Ig kappa chain V-III region; 2 spots 1 id: mouse apolipoprotein A2). The spots 1 (alpha-2-macroglobulin); 2 (complement 
C1r-subcomponent); 3 and 3a (Apoliprotein A4 and Zinc-alpha-glycoprotein 2 respectively) and 4 (glutathione peroxidase 3) 
are examples discussed respectively in the text and in Figure 5.
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Mapping of the mouse serum
As shown in Table 1, we were able to identify 90 unique
proteins, some of which were reported to be identifiable
only after sample pre-treatment or sophisticated and time-
consuming procedures. For instance, several members of
complement factor family [CFAB_MOUSE,
CFAI_MOUSE, CO3_MOUSE, CO4_MOUSE,
CO9_MOUSE and C1QB_MOUSE], properdin
[PROP_MOUSE] and mannose binding protein A
[MBL1_MOUSE] were identified at the basic pH region of
the 2-D gels. None of them were reported in previous
mouse serum proteome profiling studies using 2-DE and
MS analysis [7,8,32]. Indeed, when the serum was albu-
min-depleted, other high abundance proteins were lost as
well. Furthermore, complement factor 3 and transthyretin
were found in both fractions, albumin-rich and depleted
(Table 1) [9]. This necessitated repetitive analyses. Indeed,
complement factor 3 was shown to be up-regulated in
human lung adenocarcinomas [33], as were increased
serum levels of transthyretin and down-regulation of
transferrin in human type-2 diabetes [38].
The application of our protocol enabled an identification
of properdin [PROP_MOUSE] and adenomatous polypo-
sis coli protein [APC_MOUSE]. Once again, in previous
mouse serum maps these proteins were not identified [7-
9,32,33] (Table 1). We were able to identify most of the
proteins but some new proteins were identified as well
(Table 1). Notably, with our optimized MALDI- matrix
protocols, we were able to characterize the protein C1R
complement [C1R_MOUSE] by the sequential use of
DHB and CHCA (spot 2 in Figure 2, Figure 3). This is a
serine protease that combines with C1q and C1s (which
we had identified in our sample as well) to form C1, the
first component of the classical pathway of the comple-
ment system. The spot corresponding to C1R is positional
in the gel where the molecular weight and pH differs from
the theoretical values, presumably because of glycosyla-
tion of this protein [39]. Post-translational modifications
(PTMs) do change the chemical characteristics of the pro-
tein that runs in 2-D gels at more acidic and higher mass
ranges. Indeed, we identified glutathione peroxidase 3
[GPX3_MOUSE] (pI 8.3) in 2-D gel at pH 4–7 (spot 4 in
Figure 2, Figure 3). The gene product GPX3_MOUSE is a
secreted protein that protects cells and enzymes from oxi-
dative damage, by catalyzing the reduction of hydrogen
peroxide, lipid peroxides and organic hydroperoxide. This
protein was reported to be regulated in various malignan-
cies [40].
Without sample pre-treatments, we were able to identify
proteins such as hemopexin [HEMO_MOUSE] and alpha-
2-macroglobulin [A2MG_MOUSE]. Usually, an identifi-
cation and quantification of these proteins requires time
consuming procedures [9,32]. Here we describe a simple
protocol that allowed facile identification of the same
proteins even with a higher number of matching peptides.
For instance, spot 1 (see panel 1 in Figure 2) was identi-
fied as A2MG_MOUSE with high sequence coverage. Pre-
viously, pre-fractionation of the serum was needed to
enable its identification [32]. Likewise, with our protocol
HEMO_MOUSE was identified with a Mascot score of 188
and 21 matched peptides, a result comparable to after
immunodepletion (25 matched peptides), and pre-frac-
tionation (14 matched peptides) but considerable better
than with data from other mouse serum maps (8 matched
peptides) [7-9]. In Figure 4, we display identified proteins
where the number of matched peptides amongst different
strategies was compared; in general, we obtain a better
protein score and comparable or even higher number of
matched peptides of the protein sequence, without any
sample pre-treatment (cylinders in Figure 4, Table 1).
When no significant PMF entries were obtained, we
attempted identification by MS/MS spectra acquisition.
For instance, we acquired the LIFT TOF-TOF spectrum of
the peak yielded at m/z 1913.84 -the peptide sequence
APQVYVLPPPAEEMTKK- with an ion score of 33 and
error tolerance of 10 ppm. The peptide was then matched
to Ig gamma-2A chain C [GCAB_MOUSE]. Additionally,
we identified the secreted protein alpha-1-microglobulin
(AMBP_MOUSE) by MS/MS with the parental ion at m/z
1669.85 and a peptide sequence of TIAACNLPIVQGPCR.
We thus obtained the significant hit at ion score of 38 with
5 ppm as peptide mass tolerance; according to RMS error,
and 0.5 Da as fragment mass tolerance [21].
Furthermore, we identified a number of proteins such as
gamma actin [ACTG_MOUSE] which was believed to be
primarily cytoskeletal and/or intracellular but was not
reported so far for the mouse serum proteome. Three
peaks belonging to ACTG_MOUSE were identified at m/z
1198.75 -peptide sequence AVFPSIVGRPR- 1790.93 -pep-
tide sequence SYELPDGQVITIGNER- and 1954.14 -pep-
tide sequence VAPEEHPVLLTEAPLNPK-, with an ion
scores higher than 23. Further examples are listed in Table
1 (from number 74 to 90).
Taken collectively, our protocol enabled automated data
acquisition and improved significantly the identification
of proteins based on higher sequence coverage and the
number of matched peptides. For instance,
CFAH_MOUSE was identified with a Mascot score of 269,
a 31% sequence coverage and 29 matched peptides,
instead of 23% sequence coverage and 6 and 18 matched
peptides as reported previously (Table 1). Similarly, the
sequence coverage of apolipoprotein H (APOH_MOUSE)
was increased by 17% with 5 additional peptides that
could be mapped to this protein [7,9] (for sequence cov-
erages, please refer to Additional file 3).Proteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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Spectra comparisons between CHCA and DHB Figure 3
Spectra comparisons between CHCA and DHB. (A, B) CHCA matrix vs DHB matrix. Considerably, in the case of DHB 
the peptide ions signals are less resolved than other signals in the spectrum, maybe connected to metastable decay of ions in 
the drift tube or "chemical noises" from matrix ions. On the other hand, CHCA was enabled to identify complement C1r-sub-
component (C1r_MOUSE) and alpha-2-antiplasmin (A2AP_MOUSE). Crosses represent matched peptides to the identification. 
(C, D) DHB matrix vs CHCA matrix. The spectra from DHB are notably rich of peptides ions fragments (crosses) which 
belong to the identification, i.e. glutatione peroxidase-secreted form (GPX3_MOUSE) and gelsolin (GELS_MOUSE). The blue cir-
cles on CHCA spectra, instead, represent matrix fragments which hide the peaks could be matched to the identifications. The 
pie chart represents our mouse proteome mapping, where both matrices have the almost same input in the identifications.
CHCA
23%
DHB
24%
CHCA+DHB
53%
D
GPX3_MOUSE
CHCA
GELS_MOUSE
CHCA
C
C1R_MOUSE
CHCA
A2AP_MOUSE
CHCA
A
BProteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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Newly identified proteins
Thirteen new mouse serum proteins were identified with
our approach. Among them, some were recently con-
firmed by another group [5].
In their approach [5], however, matched peptides were
less on average when compared to our data. Apart from
this difference, a total of 6 new proteins are reported by us
(italic font in Table 2).
For instance, we identified members of complement cas-
cade activation, a positive mediator for angiogenesis
(ANGL6_MOUSE), proteins specifically regulated in sev-
eral tumor cells such as [KPYM_MOUSE] and proteins
playing an important role in protein degradation and pro-
tein ubiquitinylation, whose altered activity could allow
for abnormal cell proliferation (CUL-1_MOUSE). Nota-
bly, some of these newly identified proteins may serve as
cancer biomarkers [5,41-43].
In this regard, we identified heparan sulfate glucosamine
3-O-sulfotransferase 5 (OST-5_MOUSE), a sulfotrans-
ferase that catalyzes the transfer of a sulfo group from the
sulfo donor, 3'-phosphoadenosine-5'-phosphosulfate
(PAPS), to the 3-OH position of a glucosamine unit of the
HS. It displays anticoagulant activity by interacting with
antithrombin (AT) protein through sulfanation at the 3-
OH position of HS-saccharide [44-46]. From recent stud-
ies, new biological functions of activated HS have
emerged, for instance in regulation of cancer growth and
inflammatory responses [44,47].
Likewise, our identification of dynamin-2
(DYN2_MOUSE) in serum may be suggestive for extracel-
lular matrix degradation, in case of invasive tumor cells
(metastasis). Extensive studies are already published on
the "invasive feet" enrichments in dynamin and actin and
their involvement in extracellular matrix degradation in
hepatocellular carcinoma [48-50].
Conclusion
The combination of zoom in gels and the use of two dif-
ferent sample-matrix preparations in sequence improved
protein identification of mouse serum proteins consider-
ably and allowed for automated data acquisition as com-
pared to previous methods using 2-DE and MALDI-MS
Comparison of matched peptides Figure 4
Comparison of matched peptides. We have depicted here a comparison of some identification (x-axis) from our work 
(azure-cylinder) and three different mouse serum maps (prisms) [see ref [9,7,8]]. Note the number of matched peptides (y-
axis) is higher or comparable with the pre-fractionation methods. Mouse protein identifications: A1AG1: alpha-1-acid glycopro-
tein, A2M: alpha-2-macroglobulin, HEMO: hemopexin, APOH: beta-2-glycoprotein 1, HPT: haptoglobin, PLMN: plasminogen, 
CFAH: complement factor H, FETUA: alpha-2-HS-glycoprotein-Fetuin-A, APOE: apoliproteinE.
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(an example is given in Figure 4) [7,8]. Moreover, we
obtained a higher number of matched peptides, as com-
pared to sample pre-fractionation methods coupled with
LC-MS/MS or other proteomic approaches (Table 1)
[9,32,33]. Finally, we report an improved mouse serum
proteome map and an identification of 13 proteins that
were not reported in previous 2-DE studies. Even with the
comprehensive study reported in [5], six of them are still
novel (Table 2) [5-9,32,33]. We validated the newly iden-
tified proteins by repeating the searches against different
databases (NCBInr and MSDB), as described above (Table
2) [51]. Moreover, the same spectra were further analysed
with PeptideMap free software [22]. Altogether, identical
results were obtained.
There is a need for a reliable characterization of serum
proteomes to enable biomarker discovery. In our opinion,
the strength of this work lies in the right combination of
protocols and its simplification. We report a simple and
reliable identification of mouse serum protein (for
instance, see Figure 5) and as shown in Table 1, our work
evidences an improved identification when compared
with previous studies based on pre-treatments of serum or
other sophisticated methods.
Table 2: New proteins, spectra interpretation and validation
No No 
Table 1
Swiss 
Prot 
entry
Swiss 
Prot 
accession
putative 
PTMs
Subcellular 
location
Mw 
(KDa)
pI RMS 
error 
(ppm)
matrix Swiss 
Prot
NCBInr MSDB Nr of 
matched 
peptides 
(Mascot)
Nr of 
matched 
peptides 
(Peptide 
Map)
1 16 ANGL6 
MOUSE
Q8R0Z6 G Secreted; 
highly 
expressed in 
the liver
51.4 9 38 DHB 56 58 55 4 3
2 17 ANXA2 
MOUSE
P07356 P Secreted, 
extracellular 
space, 
extracellular 
matrix, 
basement 
membrane. 
Melanosome
38.8 8 45 CHCA 82 81 82 53
3 25 C1R 
MOUSE
Q8CG16 G Secreted 81.5 5 15 DHB 
CHCA
78 78 78 85
4 32 CS1A 
MOUSE
Q8CG14 G Predominant
ly expressed 
in liver
78.3 5 11 DHB 66 66 66 65
5 72 LAC1 
MOUSE
P01843 Secreted 11.7 6 4 DHB 70 70 70 43
6 74 ACTG 
MOUSE
P63260 P Cytoplasm, 
cytoskeleton
42.1 5 28 DHB 
CHCA
188 188 188 16 15
7 76 CT160 
MOUSE
Q8VCC6 22 10 35 CHCA 55 56 56 5 4
8 77 CUL1 
MOUSE
Q9WTX6 G Embryo 
fibroblasts 
and embryo 
preadipocyte
s
90.3 8 49 CHCA 62 62 62 76
9 81 K2C5 
MOUSE
Q922U2 P Expressed in 
epidermis
62 8 34 DHB 60 60 60 11 11
10 85 OST5 
MOUSE
Q8BSL4 G Golgi 
apparatus 
membrane; 
Single-pass 
type II 
membrane 
protein
40.7 10 35 CHCA 70 70 70 65
11 87 TPH1 
MOUSE
P17532 P Cytoplasmat
ic enzyme, 
pineal gland
51.9 6 30 CHCA 57 57 57 7 5
12 88 KPYM 
MOUSE
P52480 P Liver, red 
cells, 
muscles, 
brain
58 7 39 DHB 53 53 53 11 10
13 89 DYN2 
MOUSE
P39054 P Cytoplasm 98 7 51 DHB 
CHCA
68 68 68 99
We listed here the 13 proteins which re not present in the previous mouse serum maps [6-9,32,33].
The SwissProt entries in Italic font are proteins not identified in mouse serum proteome so far [5-9,32,33]. RMS (Root Mean Square) error is the calculated error for set of 
matched mass values (in ppm) in Mascot Search (matrix science, LTD, UK). It is measured in ppm. RMS error defines the limit of peptide mass tolerance (Peptide tol +-) for 
Mascot Peptide Mass Fingerprint to obtain a significant score (p < 0.05) of matched peptides to select protein entry.
The results were first searched in SwissProt databank and furthermore in NCBInr and MSDB databanks. The same criteria were applied (such as: mus musculus for the 
taxonomy, < +/- 50 ppm as peptide tolerance and one missed cleavage allowed for trypsin enzyme). In bold we highlighted the significant score (p < 0.05) according to the 
chosen database (SwissProt >53, NCBInr and MSDB >61) [21,51].
We also specified if one matrix or the combination of them allowed the identification.
Post translation modifications (PTMs). P: phosphorylation; G: Glycosylation.Proteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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Fast and reliable identification of mouse serum proteins Figure 5
Fast and reliable identification of mouse serum proteins. We have depicted here an example of improvement of data 
acquisition by the use narrow-pH IPG strips for the IEF. The data of score and matched peptides were chosen from the best 
outcome in MALDI-MS analysis by both matrices (CHCA and DHB) (ProteinScape™ database).
Spot 3+3a:
ZA2G: Mascot score: 67
Number of mass values matched: 8
Sequence Coverage: 29%
ZA2G: Mascot score: 173
Number of mass values matched: 15
Sequence Coverage: 55%
Spot 3a:
APOA4: Mascot score: 223
Number of mass values matched: 21
Sequence Coverage: 60%
Spot 3:
APOA4: Mascot score: 66
Number of mass values matched: 9
Sequence Coverage: 26%
IEF: 3-10 pH IEF: 4-7 pH
APOA4_MOUSE
APOA4_MOUSE
ZA2G_MOUSE
ZA2G_MOUSEProteome Science 2008, 6:25 http://www.proteomesci.com/content/6/1/25
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Taken collectively, we view our protocol to be useful in
biomarker discovery.
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